

LAURA,
on CREXONT since 2024

CREXONT: LEVODOPA DESIGNED TO LAST LONGER*

Explore how CREXONT lasted longer than RYTARY and immediate-release carbidopa/levodopa (IR CD/LD) in a clinical pharmacology study

*In a clinical pharmacology study, longest lasting was defined as how long the concentration of CREXONT, RYTARY, and IR CD/LD stayed in the blood above half the maximum concentration.

INDICATION

CREXONT® (carbidopa and levodopa) extended-release capsules is a prescription medication for the treatment of Parkinson's disease, Parkinson's disease caused by infection or inflammation of the brain, or Parkinson's disease-like symptoms that may result from carbon monoxide or manganese poisoning in adults.

IMPORTANT SAFETY INFORMATION

Do not take CREXONT with antidepressant medications known as nonselective monoamine oxidase (MAO) inhibitors.

Do not take CREXONT with other carbidopa-levodopa preparations without consulting your healthcare provider.

CREXONT may cause falling asleep during activities of daily living, somnolence, or dizziness. Avoid activities that require alertness such

as driving and operating machinery until you know how CREXONT affects you.

Your doctor should evaluate vitamin B6 levels before and during treatment with carbidopa/levodopa therapies as seizures associated with low levels of vitamin B6 have been reported. Traditional anti-seizure medications were not effective, and seizures were only resolved after vitamin B6 administration. Other symptoms of vitamin B6 deficiency include depression, confusion, cracked corners of the mouth, swollen tongue, skin inflammation, low red blood cell count, and/or numbness, tingling, or weakness in the extremities. Your doctor may advise you to take vitamin B6 as necessary.

Please see additional Important Safety Information on other pages and accompanying full Prescribing Information.

Innovation in levodopa therapy

IN A CLINICAL PHARMACOLOGY STUDY VERSUS IR CD/LD AND RYTARY

CREXONT provided the longest-lasting oral levodopa levels^{*†}

IR CD/LD has been the gold standard in Parkinson's treatment since 1970s

It works quickly but may wear off quickly, too

IR CD/LD dissolves in the stomach and may not make it to the small intestine, where it is best absorbed

When levodopa wears off quickly, doses don't last as long. So, more frequent daily dosing may be required to achieve symptom control

That's where **CREXONT** turns innovation into duration.

Immediate-release granules

Dissolve quickly, allowing them to work **within 1 hour**

Extended-release pellets

Release levodopa slowly so **levels last longer***



Capsule and contents shown for illustrative purposes only.



Immediate-release CD/LD granules



Extended-release LD pellets

CREXONT is designed to gradually release levodopa in the part of the gut where it is best absorbed[†]

[†]The exact site and duration of absorption is unknown.

^{*}In a clinical pharmacology study, longest lasting was defined as how long the concentration of CREXONT, RYTARY, and IR CD/LD stayed in the blood above half the maximum concentration.

[†]This was a post hoc analysis of a secondary measure in the clinical pharmacology study; CREXONT vs RYTARY: $P=0.010$; CREXONT vs IR CD/LD: $P<0.0001$.

IMPORTANT SAFETY INFORMATION (cont'd)

The most common side effects that may occur with CREXONT are nausea and anxiety.


It is important to avoid sudden discontinuation or rapid dose reduction of CREXONT. If you are discontinuing CREXONT, work with your healthcare provider to taper the dose over time to reduce the risk of fever or confusion.

You may take CREXONT with or without food, but taking it with food may decrease or delay its effect. Consider taking the first dose of the day about 1 to 2 hours before eating.


Swallow CREXONT whole. Do not chew, divide, or crush CREXONT capsules. If you have difficulty swallowing the capsule, twist apart both halves and sprinkle the entire contents of both halves of the capsule on a small amount of applesauce (1 to 2 tablespoons).

IN A CLINICAL PHARMACOLOGY STUDY,

Levodopa levels of CREXONT lasted longer compared with RYTARY and IR CD/LD*



CREXONT is designed to increase levodopa levels and help them last*



Levodopa levels*

CREXONT
sustained for
4.8 hours

RYTARY
sustained for
3.9 hours

IR CD/LD
sustained for
1.9 hours



CREXONT
levodopa levels
outlasted RYTARY
and IR CD/LD*†

IMPORTANT SAFETY INFORMATION (cont'd)

Consume the mixture immediately. Do not store the drug/food mixture for future use.

Do not take CREXONT with alcohol.

Tell your healthcare provider if you:

- Have any heart conditions, especially if you have had a heart attack or irregular heartbeats

- Experience hallucinations or abnormal thoughts and behaviors
- Have an inability to control urges to gamble, have increased sexual urges, or experience other intense urges
- Have thoughts of suicide or have attempted suicide
- Have abnormal involuntary movements that appear or get worse during treatment

Please see additional Important Safety Information on other pages and accompanying full Prescribing Information.

CREXONT: BUILT TO LAST



CREXONT consists of a combination of immediate release granules and innovative extended-release technology



CREXONT is designed to increase levodopa levels and make them last*



To access support and resources,
scan this QR code

*In a clinical pharmacology study, longest lasting was defined as how long the concentration of CREXONT, RYTARY, and IR CD/LD stayed in the blood above half the maximum concentration.

LAURA,
on CREXONT since 2024

IMPORTANT SAFETY INFORMATION (cont'd)

- Have ever had a peptic ulcer or glaucoma
- Become or intend to become pregnant. Based on animal data, CREXONT may cause fetal harm
- Are breastfeeding during therapy

To report **SUSPECTED ADVERSE REACTIONS**, contact Amneal Global Patient Safety at 1-877-835-5472, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Please see additional Important Safety Information on other pages and accompanying full Prescribing Information.

Amneal

CREXONT® is a registered trademark of Amneal Pharmaceuticals LLC.
© 2026 Amneal Pharmaceuticals LLC.
Distributed by Amneal Specialty, a division of Amneal Pharmaceuticals LLC.
All rights reserved. PP-ADP-CREX-US-0018 06/2026

 **CREXONT**
(carbidopa and levodopa)
EXTENDED-RELEASE CAPSULES
35mg/140mg · 52.5mg/210mg
70mg/280mg · 87.5mg/350mg